NCT07723131

Brief Summary

This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
41mo left

Started Aug 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 23, 2026

Completed
9 days until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2029

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

July 23, 2026

Status Verified

July 1, 2026

Enrollment Period

2.9 years

First QC Date

July 16, 2026

Last Update Submit

July 20, 2026

Conditions

Keywords

Aneurysmal Subarachnoid HemorrhageAneurysm ClippingCognitive Impairment

Outcome Measures

Primary Outcomes (1)

  • Montreal Cognitive Assessment (MoCA) score

    The MoCA is a global cognitive screening test with scores ranging from 0 to 30, where higher scores indicate better cognitive function. Cognitive impairment is defined as a MoCA score \<25, adjusted for educational level. A secondary analysis will also classify participants with MoCA \<23, adjusted for educational level, representing unfavorable functional outcome.

    Through study completion, an average of 3 years

Secondary Outcomes (5)

  • EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    Through study completion, an average of 3 years

  • Hospital Anxiety and Depression Scale (HADS)

    Through study completion, an average of 3 years

  • Modified Rankin Scale (mRS)

    Through study completion, an average of 3 years

  • Return to work

    Through study completion, an average of 3 years

  • In-hospital complications

    Through study completion, an average of 3 years

Study Arms (3)

Operated <24h

Patients submited to microsurgical clipping \<24h after aneurysmal subarachnoid hemorrhage

Operated 24-72h

Patients submited to microsurgical clipping between 24h and 72h after aneurysmal subarachnoid hemorrhage

Operated >72h

Patients submited to microsurgical clipping \>72h after aneurysmal subarachnoid hemorrhage

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients who underwent microsurgical clipping of ruptured cerebral aneurysms following aneurysmal subarachnoid hemorrhage (aSAH), with symptom onset occurring in or after 2020, and who are currently under outpatient follow-up at HC-UNICAMP, will be eligible for inclusion.

You may qualify if:

  • Age ≥18 years at the time of aSAH.
  • Treatment by microsurgical clipping of a ruptured cerebral aneurysm.
  • Survival until study recruitment.
  • Ability to understand and sign informed consent.

You may not qualify if:

  • Non-aneurysmal subarachnoid hemorrhage.
  • Exclusively endovascular treatment.
  • Previous diagnosis of dementia.
  • Severe neurological or psychiatric disorders unrelated to aSAH with significant cognitive impact.
  • Absolute contraindication to MRI.
  • Severe aphasia preventing adequate neuropsychological evaluation.
  • Incomplete clinical data.
  • Inability to attend in-person assessment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinics Hospital - UNICAMP

Campinas, São Paulo, 13083888, Brazil

Location

MeSH Terms

Conditions

Cognitive DysfunctionSubarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersIntracranial HemorrhagesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 16, 2026

First Posted

July 23, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

December 1, 2029

Last Updated

July 23, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will share

Yes. De-identified individual participant data will be made available upon reasonable request to the corresponding author, following publication of the primary results, subject to approval of a data access agreement and institutional/ethical requirements.

Shared Documents
STUDY PROTOCOL, ICF

Locations